论文部分内容阅读
新辅助化疗(neoadjuvant chemotherapy,NACT)作为综合治疗的一种方法在宫颈癌中主要用于治疗ⅠB2和ⅡA期的巨块型(肿瘤直径≥4 cm)晚期宫颈癌。大部分学者的研究认为,NACT能缩小肿瘤体积,提高可手术率及手术切除率,同时能降低手术并发症,有效率多高达80%以上,其中9%～18%的患者术后病理证实完全缓解。然而还有部分患者对NACT不敏感,如果对这部分患者仍进行NACT治疗就会延误治疗时机造成不必要的痛苦和浪费。近年国内外的研究者做了大量研究试图寻找出与NACT疗效相关的分子标记物,期望能够在分子水平尽早对患者进行NACT疗效预测,发现那些对NACT不敏感的患者而尽早采用其他综合治疗措施,从而改善患者的预后和生存率。综述与宫颈癌NACT疗效相关的分子标记物的研究现状。
Neoadjuvant chemotherapy (NACT) as a comprehensive treatment of cervical cancer is mainly used for the treatment of ⅠB2 and Ⅱ A period bulky (tumor diameter ≥ 4 cm) advanced cervical cancer. Most scholars believe that NACT can reduce the tumor volume, improve the rate of surgery and surgical resection, and reduce the surgical complications, the effective rate of up to 80% or more, of which 9% to 18% of patients with complete pathology confirmed ease. However, there are still some patients who are not sensitive to NACT. If NACT treatment is still performed on this part of the patients, it will delay the timing of treatment causing unnecessary suffering and waste. In recent years, researchers at home and abroad have done a great deal of research trying to find out the molecular markers related to the efficacy of NACT. The expectation is that NACT efficacy prediction can be carried out at the molecular level as soon as possible, and other comprehensive treatment measures should be taken as soon as possible for those patients who are not sensitive to NACT , Thus improving patient’s prognosis and survival rate. This review summarizes the current status of molecular markers related to the efficacy of NACT in cervical cancer.